NASDAQ: IVVD · Life Sciences · 3 alerts · CIK 1832038
Share price
$0.5377Close, Nov 16
Market cap
$159M
Shares outstanding
295.63MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Invivyd, Inc. filings on SEC EDGAR ↗
Invivyd, Inc. reported a significant increase in net loss to $119.3 million for the nine months ended September 30, 2026, compared to $41.4 million in the prior year, driven by a surge in R&D and SG&A expenses. Despite the higher loss, total revenue grew to $43.5 million from $36.2 million year-over-year, while cash and cash equivalents decreased to $126.4 million.
Invivyd reported Q3 2026 financial results, highlighted by $15.4 million in PEMGARDA net product revenue, representing 18% year-over-year growth. The company also announced that Phase 3 clinical trial data for VYD2311 is expected imminently following regulatory dialogue with the FDA regarding accelerated approval pathways.
Term
Q3 2026
“We are excited about the progress made to advance VYD2311 to meet the urgent need for new options to prevent Americans from getting sick from COVID and suffering from the debilitating impact of Long COVID or COVID vaccine injury.”
Marc Elia, Chairman and Chief Executive Officer
“PEMGARDA’s continued growth, even in the face of declining COVID vaccine utilization and announcement of the termination of its Emergency Use Authorization in mid-2027, demonstrates clear demand for monoclonal antibodies.”
Invivyd announced positive topline results from its LIBERTY Phase 3 study, which demonstrated that its COVID-19 monoclonal antibody candidate, VYD2311, had safety and tolerability superior to an mRNA-based vaccine. The company plans to use data from LIBERTY and the ongoing DECLARATION pivotal study to support a Biologics License Application (BLA) submission to the FDA via the Accelerated Approval Program.